Company intelligence / Profile preview

Baxalta

Bannockburn, Illinois, USAbaxalta.com ↗

Ownership: Public · BXLT
Employees: ~16000
Development stage: Commercial

Overview

At the time of its acquisition by Shire in June 2016, Baxalta had a robust portfolio with more than $6 billion in annual sales and over 40–60 programs in development. Its marketed products were leaders in hematology and immunology. The company was spun out from Baxter International’s BioScience business in July 2015 and quickly became a major player before being acquired by Shire for approximately $32 billion. The combined entity became the global leader in rare diseases with an expanded pipeline across multiple therapeutic areas[1][2][3][4][5].

Therapeutic areas: OncologyImmunologyHematology
Modalities: Protein therapeutics (e.g., recombinant proteins)Monoclonal antibodies (mAbs)Biosimilars
Industry: Biotech

Drug pipeline

5 assets

ADYNOVATE

Commercial

Indications: Hemophilia A

4 more assets in the full pipeline.

Partnerships

Symphogen – immuno-oncology collaboration worth up to $1.6 billion targeting six cancer antigens.

Beyond the preview

Go deeper on Baxalta.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Baxalta.